Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
Bevacizumab
Glioblastoma
Glioma
MRI
Radio-pathomic mapping
Radio-pathomics
Radiomics
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
19 Feb 2024
19 Feb 2024
Historique:
received:
03
01
2024
accepted:
30
01
2024
pubmed:
19
2
2024
medline:
19
2
2024
entrez:
19
2
2024
Statut:
aheadofprint
Résumé
Autopsy-based radio-pathomic maps of glioma pathology have shown substantial promise inidentifying areas of non-enhancing tumor presence, which may be able to differentiate subsets of patients that respond favorably to treatments such as bevacizumab that have shown mixed efficacy evidence. We tested the hypthesis that phenotypes of non-enhancing tumor fronts can distinguish between glioblastoma patients that will respond favorably to bevacizumab and will visually capture treatment response. T1, T1C, FLAIR, and ADC images were used to generate radio-pathomic maps of tumor characteristics for 79 pre-treatment patients with a primary GBM or high-grade IDH1-mutant astrocytoma for this study. Novel phenotyping (hypercellular, hypocellular, hybrid, or well-circumscribed front) of the non-enhancing tumor front was performed on each case. Kaplan Meier analyses were then used to assess differences in survival and bevacizumab efficacy between phenotypes. Phenotype compartment segmentations generated longitudinally for a subset of 26 patients over the course of bevacizumab treatment, where a mixed effect model was used to detect longitudinal changes. Well-Circumscribed patients showed significant/trending increases in survival compared to Hypercellular Front (HR = 2.0, p = 0.05), Hypocellular Front (HR = 2.02, p = 0.03), and Hybrid Front tumors (HR = 1.75, p = 0.09). Only patients with hypocellular or hybrid fronts showed significant survival benefits from bevacizumab treatment (HR = 2.35, p = 0.02; and HR = 2.45, p = 0.03, respectively). Hypocellular volumes decreased by an average 50.52 mm Patients with a hypocellular tumor front identified by radio-pathomic maps showed improved treatment efficacy when treated with bevacizumab, and reducing hypocellular volumes over the course of treatment may indicate treatment response.
Sections du résumé
BACKGROUND
BACKGROUND
Autopsy-based radio-pathomic maps of glioma pathology have shown substantial promise inidentifying areas of non-enhancing tumor presence, which may be able to differentiate subsets of patients that respond favorably to treatments such as bevacizumab that have shown mixed efficacy evidence. We tested the hypthesis that phenotypes of non-enhancing tumor fronts can distinguish between glioblastoma patients that will respond favorably to bevacizumab and will visually capture treatment response.
METHODS
METHODS
T1, T1C, FLAIR, and ADC images were used to generate radio-pathomic maps of tumor characteristics for 79 pre-treatment patients with a primary GBM or high-grade IDH1-mutant astrocytoma for this study. Novel phenotyping (hypercellular, hypocellular, hybrid, or well-circumscribed front) of the non-enhancing tumor front was performed on each case. Kaplan Meier analyses were then used to assess differences in survival and bevacizumab efficacy between phenotypes. Phenotype compartment segmentations generated longitudinally for a subset of 26 patients over the course of bevacizumab treatment, where a mixed effect model was used to detect longitudinal changes.
RESULTS
RESULTS
Well-Circumscribed patients showed significant/trending increases in survival compared to Hypercellular Front (HR = 2.0, p = 0.05), Hypocellular Front (HR = 2.02, p = 0.03), and Hybrid Front tumors (HR = 1.75, p = 0.09). Only patients with hypocellular or hybrid fronts showed significant survival benefits from bevacizumab treatment (HR = 2.35, p = 0.02; and HR = 2.45, p = 0.03, respectively). Hypocellular volumes decreased by an average 50.52 mm
CONCLUSION
CONCLUSIONS
Patients with a hypocellular tumor front identified by radio-pathomic maps showed improved treatment efficacy when treated with bevacizumab, and reducing hypocellular volumes over the course of treatment may indicate treatment response.
Identifiants
pubmed: 38372901
doi: 10.1007/s11060-024-04593-7
pii: 10.1007/s11060-024-04593-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : R01 CA218144
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA249882
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : ErratumIn
Informations de copyright
© 2024. The Author(s).
Références
Ostrom QT, Cote DJ, Ascha M et al (2018) Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol 4:1254–1262. https://doi.org/10.1001/jamaoncol.2018.1789
doi: 10.1001/jamaoncol.2018.1789
pubmed: 29931168
pmcid: 6143018
Mathew EN, Berry BC, Yang HW et al (2022) Delivering therapeutics to Glioblastoma: overcoming Biological constraints. Int J Mol Sci 23. https://doi.org/10.3390/ijms23031711
Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. https://doi.org/10.1016/S1470-2045(09)70025-7
doi: 10.1016/S1470-2045(09)70025-7
pubmed: 19269895
Wen PY, Weller M, Lee EQ et al (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22:1073–1113. https://doi.org/10.1093/neuonc/noaa106
doi: 10.1093/neuonc/noaa106
pubmed: 32328653
pmcid: 7594557
Reardon DA, Brandes AA, Omuro A et al (2020) Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 Randomized Clinical Trial. JAMA Oncol 6:1003–1010. https://doi.org/10.1001/jamaoncol.2020.1024
doi: 10.1001/jamaoncol.2020.1024
pubmed: 32437507
Garcia J, Hurwitz HI, Sandler AB et al (2020) Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017. https://doi.org/10.1016/j.ctrv.2020.102017
doi: 10.1016/j.ctrv.2020.102017
pubmed: 32335505
Arrieta VA, Chen AX, Kane JR et al (2021) ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer 2:1372–1386. https://doi.org/10.1038/s43018-021-00260-2
doi: 10.1038/s43018-021-00260-2
pubmed: 35121903
pmcid: 8818262
Yang F, He Z, Duan H et al (2021) Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nat Commun 12:3424. https://doi.org/10.1038/s41467-021-23832-3
doi: 10.1038/s41467-021-23832-3
pubmed: 34103524
pmcid: 8187342
Yuan B, Wang G, Tang X et al (2022) Immunotherapy of glioblastoma: recent advances and future prospects. Hum Vaccin Immunother 18:2055417. https://doi.org/10.1080/21645515.2022.2055417
doi: 10.1080/21645515.2022.2055417
pubmed: 35344682
pmcid: 9248956
Glas M, Ballo MT, Bomzon Z et al (2022) The impact of Tumor Treating fields on Glioblastoma progression patterns. Int J Radiation Oncology*Biology*Physics 112:1269–1278. https://doi.org/10.1016/j.ijrobp.2021.12.152
doi: 10.1016/j.ijrobp.2021.12.152
Moser JC, Salvador E, Deniz K et al (2022) The mechanisms of Action of Tumor Treating fields. Cancer Res 82:3650–3658. https://doi.org/10.1158/0008-5472.CAN-22-0887
doi: 10.1158/0008-5472.CAN-22-0887
pubmed: 35839284
pmcid: 9574373
Di Nunno V, Franceschi E, Tosoni A et al (2020) Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. Expert Rev Anticancer Ther 20:785–795. https://doi.org/10.1080/14737140.2020.1807949
doi: 10.1080/14737140.2020.1807949
pubmed: 32799576
Minniti G, Niyazi M, Alongi F et al (2021) Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol 16:36. https://doi.org/10.1186/s13014-021-01767-9
doi: 10.1186/s13014-021-01767-9
pubmed: 33602305
pmcid: 7890828
Schäfer N, Proescholdt M, Steinbach JP et al (2018) Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 20:975–985. https://doi.org/10.1093/neuonc/nox204
doi: 10.1093/neuonc/nox204
pubmed: 29121274
Nagpal S, Harsh G, Recht L (2011) Bevacizumab improves quality of life in patients with recurrent glioblastoma. Chemother Res Pract 2011:602812. https://doi.org/10.1155/2011/602812
doi: 10.1155/2011/602812
pubmed: 22312554
pmcid: 3263615
Gramatzki D, Roth P, Rushing EJ et al (2018) Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol 29:1431–1436. https://doi.org/10.1093/annonc/mdy106
doi: 10.1093/annonc/mdy106
pubmed: 29617713
Ellingson BM, Wen PY, Cloughesy TF (2018) Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro Oncol 20:457–471. https://doi.org/10.1093/neuonc/nox193
doi: 10.1093/neuonc/nox193
pubmed: 29040703
Autry A, Phillips JJ, Maleschlijski S et al (2017) Characterization of metabolic, Diffusion, and Perfusion properties in GBM: contrast-enhancing versus non-enhancing Tumor. Transl Oncol 10:895. https://doi.org/10.1016/J.TRANON.2017.08.009
doi: 10.1016/J.TRANON.2017.08.009
pubmed: 28942218
pmcid: 5612804
Lasocki A, Gaillard F (2019) Non-contrast-enhancing Tumor: a New Frontier in Glioblastoma Research. Am J Neuroradiol. https://doi.org/10.3174/ajnr.A6025
doi: 10.3174/ajnr.A6025
pubmed: 30948373
pmcid: 7053910
Nguyen HS, Milbach N, Hurrell SL et al (2016) Progressing Bevacizumab-Induced Diffusion Restriction is Associated with Coagulative Necrosis surrounded by viable tumor and decreased overall survival in patients with recurrent glioblastoma. AJNR Am J Neuroradiol 37:2201–2208. https://doi.org/10.3174/ajnr.A4898
doi: 10.3174/ajnr.A4898
pubmed: 27492073
pmcid: 5161572
Ellingson BM, Kim HJ, Woodworth DC et al (2014) Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 271:200–210. https://doi.org/10.1148/radiol.13131305
doi: 10.1148/radiol.13131305
pubmed: 24475840
Galla N, Chiang G, Chakraborty S et al (2017) Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma. Neuroradiology 59:499–505. https://doi.org/10.1007/s00234-017-1820-4
doi: 10.1007/s00234-017-1820-4
pubmed: 28343250
Bobholz SA, Lowman AK, Brehler M et al (2022) Radio-pathomic maps of cell density identify Brain Tumor Invasion beyond traditional MRI-Defined margins. AJNR Am J Neuroradiol 43:682–688. https://doi.org/10.3174/ajnr.A7477
doi: 10.3174/ajnr.A7477
pubmed: 35422419
pmcid: 9089258
Husstedt HW, Sickert M, Köstler H et al (2000) Diagnostic value of the fast-FLAIR sequence in MR imaging of intracranial tumors. Eur Radiol 10:745–752. https://doi.org/10.1007/s003300050997
doi: 10.1007/s003300050997
pubmed: 10823626
Eidel O, Neumann J-O, Burth S et al (2016) Automatic Analysis of Cellularity in Glioblastoma and correlation with ADC Using Trajectory Analysis and automatic nuclei counting. PLoS ONE 11:e0160250. https://doi.org/10.1371/journal.pone.0160250
doi: 10.1371/journal.pone.0160250
pubmed: 27467557
pmcid: 4965093
Bulik M, Jancalek R, Vanicek J et al (2013) Potential of MR spectroscopy for assessment of glioma grading. Clin Neurol Neurosurg 115:146–153. https://doi.org/10.1016/j.clineuro.2012.11.002
doi: 10.1016/j.clineuro.2012.11.002
pubmed: 23237636
Horská A, Barker PB (2010) Imaging of Brain tumors: MR Spectroscopy and metabolic imaging. Neuroimaging Clin 20:293–310. https://doi.org/10.1016/j.nic.2010.04.003
doi: 10.1016/j.nic.2010.04.003
Harris RJ, Cloughesy TF, Liau LM et al (2015) pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro Oncol 17:1514. https://doi.org/10.1093/NEUONC/NOV106
doi: 10.1093/NEUONC/NOV106
pubmed: 26113557
pmcid: 4648305
Yao J, Tan CHP, Schlossman J et al (2019) pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. J Neurooncol 142:587–595. https://doi.org/10.1007/s11060-019-03132-z
doi: 10.1007/s11060-019-03132-z
pubmed: 30806888
pmcid: 6482078
Chang PD, Malone HR, Bowden SG et al (2017) A multiparametric model for Mapping Cellularity in Glioblastoma using Radiographically localized biopsies. AJNR Am J Neuroradiol 38:890–898. https://doi.org/10.3174/ajnr.A5112
doi: 10.3174/ajnr.A5112
pubmed: 28255030
pmcid: 7960397
Gates EDH, Lin JS, Weinberg JS et al (2019) Guiding the first biopsy in glioma patients using estimated Ki-67 maps derived from MRI: conventional versus advanced imaging. Neuro Oncol 21:527–536. https://doi.org/10.1093/neuonc/noz004
doi: 10.1093/neuonc/noz004
pubmed: 30657997
pmcid: 6422438
Bobholz SA, Lowman AK, Connelly JM et al (2022) Non-invasive tumor probability maps developed using autopsy tissue identify novel areas of tumor beyond the imaging-defined margin. https://doi.org/10.1101/2022.08.17.22278910 . medRxiv
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Ashburner J, Friston KJ (2000) Voxel-based Morphometry—the methods. NeuroImage 11:805–821. https://doi.org/10.1006/NIMG.2000.0582
doi: 10.1006/NIMG.2000.0582
pubmed: 10860804
Maes F, Collignon A, Vandermeulen D et al (1997) Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 16:187–198. https://doi.org/10.1109/42.563664
doi: 10.1109/42.563664
pubmed: 9101328
Bobholz SA, Lowman AK, Barrington A et al (2020) Radiomic features of Multiparametric MRI Present stable associations with analogous histological features in patients with Brain Cancer. Tomography 6:160–169. https://doi.org/10.18383/j.tom.2019.00029
doi: 10.18383/j.tom.2019.00029
pubmed: 32548292
pmcid: 7289245
McGarry SD, Hurrell SL, Iczkowski KA et al (2018) Radio-pathomic maps of epithelium and Lumen Density predict the location of high-Grade prostate Cancer. Int J Radiat Oncol Biol Phys 101:1179–1187. https://doi.org/10.1016/j.ijrobp.2018.04.044
doi: 10.1016/j.ijrobp.2018.04.044
pubmed: 29908785
pmcid: 6190585
Duenweg SR, Fang X, Bobholz SA et al (2021) Diffusion restriction comparison between Gleason 4 fused glands and cribriform glands within patient using whole- mount prostate pathology as ground truth. Tomography 4:1–11. https://doi.org/10.3390/tomography8020053
doi: 10.3390/tomography8020053
Chen X, Zhang M, Gan H et al (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949. https://doi.org/10.1038/s41467-018-05373-4
doi: 10.1038/s41467-018-05373-4
pubmed: 30054476
pmcid: 6063898
Kitange GJ, Carlson BL, Schroeder MA et al (2009) Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11:281–291. https://doi.org/10.1215/15228517-2008-090
doi: 10.1215/15228517-2008-090
pubmed: 18952979
pmcid: 2718972